Last month, Cytori Therapeutics, Inc. (CYTX) was a featured company of the TinyGems Monthly Newsletter. Since the stock was mentioned, it has run from $1.68 to $3.51 for more than 100% gains. Volume has also increased dramatically from an approximate daily average of 350,000 to nearly one million traded shares.

If you would like sign up for the free monthly newsletter and discover new, undiscovered small-cap companies, visit www.tinygems.net.

Let us hear your thoughts below:

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Aarons Inc (AAN) Amkor Technology Inc (AMKR) Chipotle Mexican Grill Inc (CMG.B) Crocs Inc (CROX) Cytori Therapeutics Inc (CYTX) Dana Holding Corp (DAN) Depomed Inc (DEPO) Endologix Inc (ELGX) First Place Financial Corp (FPFC) Green Mountain Coffee Roasters Inc (GMCR) Hecla Mining Co (HL) Internet Initiative Japan Inc (IIJI) Mag Silver Corp (MVG) Marten Transport Ltd (MRTN) Medco Health Solutions Inc (MHS) Mercury Computer Systems Inc (MRCY) MutualFirst Financial Inc (MFSF) Navios Maritime Partners LP (NMM) Nissan Motor Co Ltd (NSANY) Nu Skin Enterprises Inc (NUS) Old Republic International Corp (ORI) Rackspace Hosting Inc (RAX) S Y Bancorp Inc (SYBT) Siliconware Precision Industries (SPIL) Skyworks Solutions Inc (SWKS) TriQuint Semiconductor ...

Cytori has developed technology designed to assist the physician in reconstructive and aesthetic surgery procedures. The company’s mission is to improve the quality and length of life by providing innovative regenerative therapies to patients. Their key technology is the Celution® 700 system that prepares an autologous tissue graft for delivery back to the patient in the same surgical procedure.

Although Celution® is currently unavailable in the U.S., the technology is under review by the US Food and Drug Administration (FDA) and commercially available in many countries in Europe and Asia. Cytori is actively pursuing the expansion of their distributor network to target distributor partnerships in South America as well as other regions. The company is also investigating the possibility of using their technology for indications beyond reconstructive and aesthetic surgery.

The Celution® 900/MB System is the foundation of the company’s StemSource™ Cell Bank. This cell bank enables hospitals in Japan to

...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Amtrust Financial Services Inc (AFSI) AP Pharma Inc (APPA) Becton Dickinson and Co (BDX) Calavo Growers Inc (CVGW) Cytori Therapeutics Inc (CYTX) Dassault Systemes SA (DASTY) Decode Genetics Inc (DCGN) Dillard's Inc (DDS) Endologix Inc (ELGX) Haemonetics Corp (HAE) Ivanhoe Mines Ltd (IVN) Linktone Ltd (LTON) Navisite Inc (NAVI) Nile Therapeutics Inc (NLTX) Novavax Inc (NVAX) NSTAR (NST) Orchids Paper Products Co (TIS) Papa John's Int'l Inc (PZZA) Provident Energy Trust (PVX) Stericycle Inc (SRCL) TAM SA (TAM) Tucows Inc (TCX) Winner Medical Group Inc (WMDG) View the entire Zacks #1 Rank List.

Zacks Investment Research

We continue to be very positive on Cytori Therapeutics Inc. (CYTX) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years. Initial sales in 2008 were encouraging.

Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing, additional data expected over the next few years will have an immediate impact on the financial results.

Even after this morning's 19% gains following President Obama's announced a reversal of policy regarding the stem cell industry, we feel Cytori's share price represents a very attractive entry point. We are maintaining our Buy rating and $8 target. Zacks Investment Research

We continue to be very positive on Cytori Therapeutics Inc. (CYTX) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years. Initial sales in 2008 were encouraging.Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing, additional data expected over the next few years will have an immediate impact on the financial results.Even after this morning's 19% gains following President Obama's announced a reversal of policy regarding the stem cell industry, we feel Cytori's share price represents a very attractive entry point. We are maintaining our Buy rating and $8 target. Read the full analyst report on "CYTX"Zacks Investment Research

a onblur=”try {parent.deselectBloggerImageGracefully();} catch(e) {}” href=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s1600-h/stem_cells.jpg”img style=”float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px; height: 169px;” src=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s200/stem_cells.jpg” border=”0″ alt=”"id=”BLOGGER_PHOTO_ID_5298815068233289618″ //abr /Since President Obama has decided to repeal the limitations imposed on embryonic stem cell research, and since the first federally approved human study utilizing embryonic stem cell therapy is now taking place, investors are now looking at opportunities in stem cell stocks. Extensive research is being done to utilize stem cells for a href=”http://stockerblog.blogspot.com/2008/05/gene-therapy-stocks.html” target-”_blank”gene therapy/a and the treatment of multiple sclerosis, Parkinson’s disease, heart disease, diabetes, arthritis, and many other medical conditions. br /br /A source of stem cells is a href=”http://cordbloodstocks.com/” target-”_blank”cord blood/a, the blood from an umbilical cord. The saving and storing of cord blood has become a fast growing business. For example, Richard Branson, founder and head of Virgin Records and Virgin Atlantic Airways, set up a cord blood bank. Even a href=”http://stockerblog.blogspot.com/2007/10/stem-cell-bonds-issued-by-california.html” target-”_blank”Stem Cell …

Biotech companies are a great investment right now, says Laura Cadden. And support from the Obama administration will ensure this trend continues. Laura picks four small cap biotech firms set to soar.

This from Today’s Financial News:

We’ve already taken double-digit gains on Aastrom Biosciences, Inc. (NASDAQ:ASTM),  Cerus Corporation (NASDAQ:CERS), and Geron Corporation (NASDAQ:GERN).

But these stocks are by no means done with their upward momentum.

Biotech companies continue to be a great investment – and these three are some of the best out there.

As the market takes another hit and these stocks artificially deflate, I recommend that TFN investors should again pick up shares.

And I’ve found another company that I believe is on the verge of a breakout.

But first, what’s so great about the three companies I selected in November? Let’s review… Aastrom Biosciences, Inc. (NASDAQ:ASTM) develops products for the repair or regeneration of human tissue. It’s

...